Jim Cramer Criticizes Molina Healthcare Over Government Program Exposure

Jim Cramer singled out Molina Healthcare (MOH) during a recent market commentary, warning investors about the company’s significant exposure to Medicare and Medicaid programs. He described these segments as 'the weakest part of a weak business,' signaling growing concern over the sustainability of revenue streams tied to federal and state government health programs. Molina's financial performance in recent quarters has reflected this pressure, with Medicare and Medicaid accounting for approximately 78% of its total revenue in 2025, according to publicly available filings. The company reported a 4.3% decline in adjusted earnings per share for the fourth quarter of 2025, compared to the same period the previous year. At the same time, its operating margin contracted to 4.1%, down from 5.6% in 2024, partly due to rising administrative costs and lower reimbursement rates in government programs. These metrics underscore challenges in managing profitability within regulated public health markets. The stock has underperformed the broader healthcare sector, with MOH down 12.7% year-to-date as of March 2026, compared to a 2.1% gain in the S&P 500 Health Care Sector ETF (XLV). Meanwhile, pharmaceutical giant Amgen (AMGN) has posted strong revenue growth, highlighting divergent trends across the healthcare landscape. Investors are increasingly focusing on firms with diversified revenue models, reducing appetite for companies like Molina that depend heavily on a single, policy-sensitive segment. Cramer’s remarks, while not based on new financial disclosures, amplify existing market concerns. The commentary may influence short-term trading sentiment, particularly among retail investors following his commentary. However, the broader market impact remains limited, as Molina represents a small portion of the healthcare index and its risks are seen as company-specific rather than systemic.